NAS:NBIX (USA)
Â
Ordinary Shares
$
138.48
+2.33 (+1.71%)
10:08 PM EST
Current and historical daily PE Ratio for Neurocrine Biosciences Inc (
) from 1996 to May 15 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Neurocrine Biosciences stock (NBIX) PE ratio as of May 15 2024 is 38.15.
More Details
Neurocrine Biosciences Inc (NBIX) PE Ratio (TTM) Chart
Neurocrine Biosciences Inc (NBIX) PE Ratio (TTM) Historical Data
View and export this data going back to 1996. Start your Free Trial
Total 1229
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Neurocrine Biosciences PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-15 | 38.1 | 2024-03-12 | 56.9 |
| 2024-05-14 | 38.1 | 2024-03-11 | 57.3 |
| 2024-05-13 | 37.5 | 2024-03-08 | 57.5 |
| 2024-05-10 | 37.7 | 2024-03-07 | 55.9 |
| 2024-05-09 | 38.5 | 2024-03-06 | 54.6 |
| 2024-05-08 | 38.3 | 2024-03-05 | 55.2 |
| 2024-05-07 | 39.5 | 2024-03-04 | 55.0 |
| 2024-05-06 | 39.0 | 2024-03-01 | 54.3 |
| 2024-05-03 | 38.8 | 2024-02-29 | 53.9 |
| 2024-05-02 | 38.5 | 2024-02-28 | 55.6 |
| 2024-05-01 | 39.4 | 2024-02-27 | 56.2 |
| 2024-04-30 | 37.9 | 2024-02-26 | 56.0 |
| 2024-04-29 | 38.3 | 2024-02-23 | 55.5 |
| 2024-04-26 | 37.5 | 2024-02-22 | 55.1 |
| 2024-04-25 | 38.0 | 2024-02-21 | 54.0 |
| 2024-04-24 | 38.3 | 2024-02-20 | 54.8 |
| 2024-04-23 | 38.6 | 2024-02-16 | 54.7 |
| 2024-04-22 | 36.8 | 2024-02-15 | 55.4 |
| 2024-04-19 | 36.4 | 2024-02-14 | 54.5 |
| 2024-04-18 | 36.5 | 2024-02-13 | 55.3 |
| 2024-04-17 | 36.7 | 2024-02-12 | 53.9 |
| 2024-04-16 | 36.6 | 2024-02-09 | 54.7 |
| 2024-04-15 | 36.3 | 2024-02-08 | 55.5 |
| 2024-04-12 | 37.1 | 2024-02-07 | 56.3 |
| 2024-04-11 | 37.5 | 2024-02-06 | 59.1 |
| 2024-04-10 | 38.0 | 2024-02-05 | 58.5 |
| 2024-04-09 | 38.3 | 2024-02-02 | 58.6 |
| 2024-04-08 | 38.4 | 2024-02-01 | 58.9 |
| 2024-04-05 | 38.3 | 2024-01-31 | 57.8 |
| 2024-04-04 | 37.9 | 2024-01-30 | 58.7 |
| 2024-04-03 | 37.9 | 2024-01-29 | 58.8 |
| 2024-04-02 | 37.9 | 2024-01-26 | 58.7 |
| 2024-04-01 | 39.0 | 2024-01-25 | 58.3 |
| 2024-03-28 | 38.0 | 2024-01-24 | 57.9 |
| 2024-03-27 | 57.0 | 2024-01-23 | 58.0 |
| 2024-03-26 | 58.3 | 2024-01-22 | 57.8 |
| 2024-03-25 | 58.0 | 2024-01-19 | 56.8 |
| 2024-03-22 | 58.4 | 2024-01-18 | 56.5 |
| 2024-03-21 | 59.4 | 2024-01-17 | 56.7 |
| 2024-03-20 | 58.1 | 2024-01-16 | 54.8 |
| 2024-03-19 | 58.2 | 2024-01-12 | 54.6 |
| 2024-03-18 | 57.6 | 2024-01-11 | 54.0 |
| 2024-03-15 | 57.5 | 2024-01-10 | 54.7 |
| 2024-03-14 | 57.5 | 2024-01-09 | 55.3 |
| 2024-03-13 | 58.6 | 2024-01-08 | 55.4 |
Neurocrine Biosciences Inc (NBIX) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Neurocrine Biosciences Inc
NAICS : 325414
SIC : 2836
ISIN : US64125C1099
Share Class Description:
NBIX: Ordinary SharesCompare
Compare
Traded in other countries / regions
NBIX.USAN1BI34.BrazilNB3.Germany0K6R.UK IPO Date
1996-05-23Description
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers